Vivesto AB

VIVE · Nasdaq Stockholm · Healthcare

8.34SEK −0.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −58.0%

Performance

1 month

−6.7%

1 year

−58.0%

3 years, per year

−24.9%

5 years, per year

−47.2%

Largest fall, 3 years

−96.2%

Below the peak now

−99.5%

Volatility, 1 year

62.4%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.6

Dividend yield

0.0%

Return on equity

−19.9%

Net margin

−189.4%

Market value

9 m USD

Quality, value and trend

Where Vivesto stands against every Nordic stock today. 100 is best.

Quality57

Profitability and a sound balance sheet over time. Better than 57% of Nordic stocks.

Value24

The price measured against earnings, assets and cash flow. Better than 24% of Nordic stocks.

Trend27

The price development over the past year. Better than 27% of Nordic stocks.

Combined23

Quality, value and trend together. Better than 23% of Nordic stocks.

About Vivesto

Vivesto AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis